Member Contact: A. Prof. Ashley Mansell
Position: Senior Director of Research and Development
Industry: Biotech & Pharmaceuticals
Morningside Biopharma Advisory (MBA) is a biopharmaceutical incubator that brings innovative therapies rapidly to market by building a portfolio of companies around prototype assets focused on infection, immunity and inflammation. MBA is backed by Morningside Ventures, who have an established an enviable reputation over its several decades of existence as an independently-minded, science-focused, life sciences investor. During the past several years,
Morningside has advanced some of its portfolio build through the shared services of MBA under the leadership of its internal team of highly experienced biopharma executives and entrepreneurs. Our innovative and globally sourced assets have begun to advance through discovery and into clinical development, and now form the basis of 4 companies within Morningside Ventures’ extensive portfolio of companies. MBA’s operating model provides the financial wherewithal, timing, expertise, and ability to grow our science into therapeutic opportunities with meaningful patient benefit, protected IP and large commercial market opportunities.
We select and advance promising therapeutics by rigorous diligence around the associated disease biology in addition to close engagement with recognized world experts, who inspire and guide us to translate their life’s work into novel human treatments.
Moreover, we are a close-knit team which operates in a highly collaborative manner, and where all are encouraged to think of themselves as “owner executives.” If you are a self-starter, willing to roll up your sleeves and eager to bring your experience to a fast paced, patient-focused biotech incubator with an opportunity that spans multiple companies, research platforms, and therapeutic areas, then we would love to get to know you.